全球 CD22 標靶療法市場 - 已批准藥物銷售、技術平台和臨床試驗展望 (2026)

全球 CD22 標靶療法市場 - 已批准藥物銷售、技術平台和臨床試驗展望 (2026) 報告的主要發現和要點：

• 當前與未來全球市場展望
• CD22 標靶療法的洞察
• 已核准藥物劑量、價格和銷售分析
• 依地區和適應症劃分的 CD22 標靶療法發展趨勢
• 正在進行臨床試驗的 CD22 標靶療法：超過 20 種療法
• 依公司、國家、適應症和研發階段劃分的 CD22 標靶療法臨床試驗分析
• 各公司專有的 CD22 標靶療法技術

對 CD22 標靶療法的需求及其重要性報告

癌症治療格局的不斷變化推動了對標靶CD22蛋白療法的需求。 CD22蛋白存在於B細胞表面，並在多種血液腫瘤中過度表達，包括急性淋巴性白血病、大B細胞淋巴瘤和毛細胞白血病。這些療法可望提供更精準有效的治療選擇，尤其適用於已用盡常規治療方案的復發或難治性疾病患者。本報告旨在為利害關係人提供CD22標靶療法的現狀概述，並深入了解推動該領域創新的臨床試驗、技術平台和關鍵參與者。

本報告包​​含的臨床研究和試驗見解

本報告對正在進行的CD22標靶臨床研究和試驗進行了全面分析，涵蓋了廣泛的地區、患者群體和治療方法。本報告包​​含單藥療法和聯合療法的數據，重點介紹了將靶向 CD22 的藥物與其他療法（例如靶向 CD19 和 CD20 的療法）聯合使用的治療潛力。本報告還概述了臨床試驗申辦方，使利害關係人能夠清楚了解推動 CD22 標靶療法開發的公司、學術機構和研究組織。此外，報告還提供了區域性見解，使研究人員能夠識別新興市場以及 CD22 標靶療法應用正在蓬勃發展或面臨監管挑戰的地區。

本報告涵蓋的技術平台

本報告的一大亮點是其對創新技術平台的詳細分析，這些平台正在顯著改變 CD22 標靶療法的開發方式。例如，Cellectis 公司的 TALEN®（轉錄活化因子樣效應核酸酶）是一種基因編輯平台，可實現精確的基因組編輯，特別適用於 Lasme-cel (UCART22) 和 Eti-cel (UCART20x22) 等細胞療法的開發。 TALEN® 技術能夠實現高度精準的基因修飾，包括基因敲除、插入和缺失，從而開發出更有效、更具標靶性的療法。本報告深入探討了這些平台及其在 CD22 領域的應用，並闡述了這些技術如何重新定義細胞免疫療法的未來。

參與 CD22 標靶療法研發的關鍵公司

本報告也重點介紹了推動 CD22 標靶療法研發的關鍵公司。這些公司包括輝瑞、阿斯特捷利康和 Umoja Biopharma 等大型生物技術和製藥公司。新興公司專注於細胞療法和創新遞送系統。本報告分析了這些公司正在採取的策略、已取得的進展以及它們將 CD22 標靶療法推向癌症治療前沿的潛力。深入了解每家公司的研發管線和開發重點，有助於利害關係人更準確地評估這一前景廣闊的治療領域的發展方向。

報告：CD22標靶療法的未來發展方向

本報告旨在指導CD22標靶療法的未來發展方向，該領域正不斷發展演進。從CAR-T細胞療法的進展到奈米抗體技術的整合，本報告指明了下一波創新浪潮。如前文所述，新型聯合療法和多標靶策略可望克服抗原逃脫和復發等關鍵挑戰，從而提高治療效果和患者預後。本報告將成為利害關係人了解CD22標靶療法未來發展方向以及探索如何在快速發展的領域中取得成功的重要工具。

目錄

第一章：研究方法

第二章：CD22簡介

• CD22標靶療法概述
• CD22在免疫學中的重要性

第三章：CD22生物學

• CD22的結構與功能
• 在B細胞發育與功能中的作用
• 在免疫反應中的作用機制

第四章：CD22標靶治療方法

• 細胞療法
• 抗體療法
• 放射免疫偶聯物
• 核療法酸類

第五章：全球 CD22 標靶治療市場展望

• 當前市場概況
• 未來市場機遇

第六章：贊助劑量、定價與銷售洞察

• 概述與可用性洞察
• 定價與劑量洞察
• 銷售洞察

第七章：CD22 標靶治療區域市場分析

• 美國
• 歐洲

第八章：CD22 標靶治療的發展與臨床趨勢（依適應症劃分）

• 癌症
• 神經退化性疾病
• 自體免疫疾病與發炎性疾病疾病
• 傳染病

第九章：全球 CD22 標靶治療臨床試驗概論

• 依國家劃分
• 依適應症劃分
• 依機構劃分
• 依階段劃分

第十章：全球 CD22 標靶治療臨床試驗洞察（依公司、國家、適應症和階段劃分）

• 研究
• 臨床前研究
• I 期研究
• I/II 期研究
• 註冊前研究

第十一章：已上市 CD22 標靶治療的臨床洞察：依公司、國家、適應症和階段劃分

第十二章：全球 CD22 標靶治療市場動態

• 推動因素和機遇
• 挑戰與解決方案

第十三章：各公司CD22標靶治療開發平台

第十四章：競爭格局

• ADC Therapeutics
• 阿斯特捷利康
• Autolus Therapeutics
• Cellectis
• Century Therapeutics
• Enterome
• Essen BioTech
• Kecellitics Biotech
• ME Therapeutics
• Miltenyi Biomedicine
• 南京艾奧生物技術
• NanoCell Therapeutics
• Onechain Immunotherapeutics
• 輝瑞
• Regeneron
• 上海亞科生物技術
• 希諾美生物科學
• TuHURA 生物科學公司
• Umoja 生物製藥

Global CD22 Targeted Therapies Market, Approved Drug Sales, Technology Platforms and Clinical Trials Insight 2026 Report Findings & Highlights:

• Current & Future Global Market Outlook
• Insight On CD22 Targeted Approaches
• Approved Drug Dosage, Price & Sales Insight
• CD22 Targeted Therapies Development Trends By Region & Indications
• CD22 Targeted Therapies In Clinical Trials: > 20 Therapies
• CD22 Targeted Therapies Clinical Trials Insight By Company, Country, Indication and Phase
• CD22 Targeted Therapies Proprietary Technologies By Company

CD22 Targeted Therapies Need & Why This Report?

As the landscape of cancer therapies evolves, there is an increasing demand for treatments that specifically target the CD22 protein, which is found on the surface of B-cells and is overexpressed in several blood cancers, including acute lymphoblastic leukemia, large B-cell lymphoma and hairy cell leukemia. These therapies offer the potential for more precise, effective options, especially for patients with conditions in relapsed or refractory states who have exhausted conventional therapies. The report is designed to give stakeholders an overview of the current landscape regarding CD22 targeted therapies, offering an understanding of clinical trials, technological platforms, and key players driving innovation in the space.

Clinical Studies & Trials Insight Included In Report

This report provides comprehensive analysis for ongoing clinical studies and trials targeting CD22, covering a wide array of geographies, patient segments, and therapeutic approaches. Insights include data on monotherapies and combination therapies, highlighting the therapeutic potential of combining agents targeting CD22 with other treatments, such as CD19 or CD20 directed therapies. The report also covers trial sponsors, giving stakeholders a clear view on which companies, academia, and research institutes are advancing the development of treatments utilizing CD22. Additionally, it provides regional insights that allow for the identification of emerging markets and regions where the adoption of CD22 targeted therapies is gaining momentum or facing regulatory challenges.

Technology Platforms Included In Report

One of the key highlights of the report is the in-depth analysis of innovative technology platforms that are dramatically changing how CD22 targeted therapies are developed. For example, TALEN(R) (Transcription Activator-Like Effector Nucleases) by Cellectis is a gene-editing platform that enables precise genome editing and proves especially instrumental in cell therapy development, including Lasme-cel (UCART22) and Eti-cel (UCART20x22). TALEN(R) technology enables highly accurate gene modifications, such as knockouts, insertions, and deletions, allowing for the manufacturing of more effective and targeted treatments. The report provides an in-depth review of such platforms and their application in the CD22 space, giving insight into how these technologies are redefining the future of cell-based immunotherapies.

Leading Companies Engaged In R&D Of CD22 Targeted Therapies

The report also profiles the leading companies driving research and development in CD22 targeted therapies, including major biotech and pharmaceutical companies such as Pfizer, AstraZeneca, and Umoja Biopharma, among others. Emerging players specialize in cell-based therapies and innovative delivery systems. This report analyzes the strategies being pursued, progress made, and the potential for these companies to bring CD22 targeted therapies to the forefront of cancer treatment. Gaining insight into a company's research pipeline and development priorities enables stakeholders to more accurately assess the direction of this exciting therapeutic area.

Report Indicating Future Direction Of CD22 Targeted Therapies

This report provides the future direction of these therapies as the landscape of CD22 targeted therapies continuously evolves. The next waves of innovation, from advances in CAR-T cell therapies to the integration of nanobody based technologies, are identified in this report. As explained, new combinations and multi target approaches have the potential to overcome major challenges such as antigen escape and relapse and, therefore, will drive improved efficacy and patient outcomes. This report is an important tool for stakeholders seeking to understand where CD22 targeted therapies are headed and how to position themselves for success in this rapidly developing field.

Table of Contents

1. Research Methodology

2. Introduction To CD22

• 2.1 Overview Of CD22 Targeted Therapies
• 2.2 Importance Of CD22 In Immunology

3. Biology Of CD22

• 3.1 Structure & Function of CD22
• 3.2 Role In B-cell Development & Function
• 3.3 Mechanisms Of Action In Immune Response

4. CD22 Targeted Approaches

• 4.1 Cell Therapies
• 4.2 Antibody Therapies
• 4.3 Radioimmunoconjugates
• 4.4 Nucleic Acids

5. Global CD22 Targeted Therapies Market Outlook

• 5.1 Current Market Scenario
• 5.2 Future Market Opportunities

6. Besponsa - Dosage, Price & Sales Insight

• 6.1 Overview & Availability Insight
• 6.2 Pricing & Dosage Insight
• 6.3 Sales Insight

7. CD22 Targeted Therapies Regional Market Analysis

• 7.1 US
• 7.2 Europe

8. CD22 Targeted Therapies Development & Clinical Trends By Indication

• 8.1 Cancer
• 8.2 Neurodegenerative Diseases
• 8.3 Autoimmune & Inflammatory Diseases
• 8.4 Infectious Diseases

9. Global CD22 Targeted Therapy Clinical Trials Overview

• 9.1 By Country
• 9.2 By Indication
• 9.3 By Organization
• 9.4 By Phase

10. Global CD22 Targeted Therapy Clinical Trials Insight By Company, Country, Indication & Phase

• 10.1 Research
• 10.2 Preclinical
• 10.3 Phase I
• 10.4 Phase I/II
• 10.5 Preregistration

11. Marketed CD22 Targeted Therapies Clinical Insight By Company, Country, Indication & Phase

12. Global CD22 Targeted Therapies Market Dynamics

• 12.1 Drivers & Opportunities
• 12.2 Challenges & Solutions

13. CD22 Targeted Therapies Development Platforms By Company

14. Competitive Landscape

• 14.1 ADC Therapeutics
• 14.2 AstraZeneca
• 14.3 Autolus Therapeutics
• 14.4 Cellectis
• 14.5 Century Therapeutics
• 14.6 Enterome
• 14.7 Essen BioTech
• 14.8 Kecellitics Biotech
• 14.9 ME Therapeutics
• 14.10 Miltenyi Biomedicine
• 14.11 Nanjing IASO Biotechnology
• 14.12 NanoCell Therapeutics
• 14.13 Onechain Immunotherapeutics
• 14.14 Pfizer
• 14.15 Regeneron
• 14.16 Shanghai Yake Biotechnology
• 14.17 SinoMab Bioscience
• 14.18 TuHURA Biosciences
• 14.19 Umoja Biopharma

List of Figures

• Figure 2-1: CD22 As A Therapeutic Target
• Figure 2-2: Evolution Of CD22 Targeted Therapy
• Figure 2-3: CD22 In Immune Regulation
• Figure 2-4: CD22 In The B-Cell Signaling Network
• Figure 2-5: How CD22 Dampens BCR Signaling
• Figure 3-1: Domain Architecture Of CD22
• Figure 3-2: CD22 Mediated Inhibition Of BCR Signaling
• Figure 3-3: Dual Signaling Roles Of CD22
• Figure 3-4: CD22 Oligomerization & B-Cell Activation Threshold
• Figure 3-5: CD22 Adhesion & Immune Synapse Positioning
• Figure 3-6: CD22 In Calcium Regulation
• Figure 3-7: CD22's Multi-Layered Control Of Immune Responses
• Figure 4-1: CD22 Targeted CAR-T Cell Therapy - Mechanism
• Figure 4-2: Targeting CD22 After CD19 Antigen Escape
• Figure 4-3: Multi-Antigen CAR Concept Featuring CD22
• Figure 4-4: CD22 Targeted Antibody Based Therapies
• Figure 4-5: Besponsa - Mechanism Of Action
• Figure 4-6: Lumoxiti - Mechanism Of Action
• Figure 4-7: CD22-Targeted Radioimmunoconjugates - Mechanism Of Action
• Figure 4-8: CD22 Radioimmunoconjugates - Advantages
• Figure 4-9: CD22 Nucleic Acid Targeting Approaches
• Figure 4-10: Targeting CD22 With RNA-Based Therapeutics
• Figure 5-1: CLIC-02 Phase 1 (NCT06208735) Study - Initiation & Completion Year
• Figure 5-2: Global CD22 Targeted Therapies Market - Future Opportunities
• Figure 6-1: Besponsa - Approval Year By Region
• Figure 6-2: Besponsa - Cost Of Supply By Region, November'2025
• Figure 6-3: Besponsa - Global Annual Sales (US$ Million), 2020-2023
• Figure 6-4: Besponsa - Global Sales by Region (US$ Million), 2023
• Figure 6-5: Besponsa - Global Quarterly Sales (US$ Million), Q1-Q4'2023
• Figure 8-1: SIDNEY Phase 1/2 (NCT04669171) Study - Initiation & Completion Year
• Figure 8-2: BZE2204-A-01 Phase 1 (NCT06446128) Study - Initiation & Completion Year
• Figure 8-3: BZE2204-C-01 Phase 1 (NCT07174843) Study - Initiation & Completion Year
• Figure 9-1: Global - Number Of CD22 Targeted Therapy Clinical Trials By Country, 2026
• Figure 9-2: Global - Number Of CD22 Targeted Therapy Clinical Trials By Indication, 2026
• Figure 9-3: Global - Number Of CD22 Targeted Therapy Clinical Trials By Organization, 2026
• Figure 9-4: Global - Number Of CD22 Targeted Therapy Clinical Trials By Phase, 2026
• Figure 12-1: Global CD22 Targeted Therapies Market - Drivers & Opportunities
• Figure 12-2: Global CD22 Targeted Therapies Market - Challenges & Solutions
• Figure 13-1: TRAAC - Tallac Therapeutics
• Figure 13-2: VivoVec Platform - Unique Features
• Figure 13-3: OncoMimics Platoform
• Figure 13-4: Cellectis - TALEN Technology

List of Tables

• Table 3-1: CD22 Functions Across B-Cell Stages
• Table 4-1: CD22 Directed Antibody Based Therapies